ReachMD CME
by ReachMDYour professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
Copyright: Copyright 2024 ReachMD. All rights reserved.
Episodes
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
0s · PublishedValid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
0s · PublishedValid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-biomarkers-of-response-to-immunotherapeutic-regimens/24356/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Overcoming Barriers to Equitable Care in HNSCC
0s · PublishedValid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/program-name/24357/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
0s · PublishedValid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/evolutions-in-duchenne-muscular-dystrophy-treatment-implications-for-the-present-and-future/20369/
There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitable therapy for each patient is a developing process. This education covers dystrophin disruption and restoration, recent clinical trial outcomes from different treatment methods, and a case study exploring novel patient management strategies.
=Not All Therapy Needs to Be Swallowed or Injected: The Future of Digital Therapeutics to Alleviate the Negative Symptoms of Schizophrenia
0s · PublishedValid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/not-all-therapy-needs-to-be-swallowed-or-injected-the-future-of-digital-therapeutics-to-alleviate-the-negative-symptoms-of-schizophrenia/20300/
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Integration Is the Key to Success: How Will the New SCZ Therapies Fit Into Clinical Treatment Paradigms?
0s · PublishedValid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/integration-is-the-key-to-success-how-will-the-new-scz-therapies-fit-into-clinical-treatment-paradigms/20299/
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
Tools of the Trade: Measurement-Based Care for CIAS
0s · PublishedValid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/tools-of-the-trade-measurement-based-care-for-cias/20295/
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
ACC 2024: The PIONEER AF-PCI Trial
0s · PublishedValid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/acc-2024-the-pioneer-af-pci-trial/24404/
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
ACC 2024: What's Really New in Electrophysiology That Will Change My Practice?
0s · PublishedValid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/acc-2024-whats-really-new-in-electrophysiology-that-will-change-my-practice/24405/
This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.
Glycine's Role in Driving the Cognitive Symptoms of CIAS
0s · PublishedValid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/glycines-role-in-driving-the-cognitive-symptoms-of-cias/20292/
This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.
ReachMD CME has 2241 episodes in total of non- explicit content. Total playtime is 0:00. The language of the podcast is English. This podcast has been added on November 27th 2022. It might contain more episodes than the ones shown here. It was last updated on May 31st, 2024 01:40.